Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 6/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 5/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492838 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL29354999 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL16081269 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL120439 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL2461163 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL12264514 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL19807522 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL3950346 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL9498481 | 0.99 | ADORA3 (0.98) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL4803030 | 0.99 | ADORA3 (0.98) | ADORA3ADORA2AADORA1ADORA2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118845814-A | Application of N6-cyclopentyl adenosine, derivatives and salts thereof in treating liver diseases | 上海中医药大学 | 2024-10-29 | — | — | CN | claimed |
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | claimed |
| CN-111789950-A | Method and pharmaceutical composition for regulating fear memory consolidation | 浙江大学 | 2020-10-20 | — | — | CN | claimed |
| EP-2704793-B1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV RAMOT (IL) | 2019-07-17 | — | — | EP | claimed |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2018-12-06 | — | — | US | claimed |
| WO-2016183217-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY (US) | 2016-11-17 | — | — | WO | claimed |
| EP-2204154-B1 | Association of monosaccharides and adenosine and its cosmetic use | ORÉAL L (FR) | 2016-10-12 | — | — | EP | claimed |
| US-9192670-B2 | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-11-24 | — | — | US | claimed |
| US-20140147516-A1 | POLYMORPHISMS PREDICTIVE OF PLATINUM-COORDINATING COMPOUND-INDUCED OTOTOXICITY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-05-29 | — | — | US | claimed |
| EP-2704793-A1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Ramot at Tel Aviv University, Ltd. (IL) | 2014-03-12 | — | — | EP | claimed |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | L'OREAL (FR) | 2010-07-01 | — | — | US | claimed |
| WO-2009124396-A1 | POLYMORPHISMS PREDICTIVE OF PLATINUM-COORDINATING COMPOUND-INDUCED OTOTOXICITY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-10-15 | — | — | WO | claimed |
| US-20070232560-A1 | Treatment of skin with adenosine or adenosine analog | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2007-10-04 | — | — | US | claimed |
| EP-1424064-B1 | Use of adenosin or an adenosin analog to smooth out fine lines | OREAL (FR) | 2007-06-06 | — | — | EP | claimed |
| WO-2007042679-A2 | COSMETIC COMPOSITION CONTAINING A NON-PHOSPHATE COMPOUND BASED ON ADENOSINE AND A TIGHTENING POLYMER | L'OREAL (FR) | 2007-04-19 | — | — | WO | claimed |
| US-20060240056-A1 | Treatment of skin with adenosine or adenosine analog | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2006-10-26 | — | — | US | claimed |
| EP-1638579-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005003150-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2005-01-13 | — | — | WO | claimed |
| EP-1424064-A1 | Use of adenosin or an adenosin analog to smooth out fine lines | L'OREAL (FR) | 2004-06-02 | — | — | EP | claimed |
| US-5998423-A | IN SKIN OR HAIR; ADMINISTERING ADENOSINE RECEPTOR ANTAGONIST | THERASYS, INC. (US) | 1999-12-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | ADORA3 32/4885ADORA2A 10/4885ADORA1 39/4885 |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA2A 1/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.